Journal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
Volume 49, Issue 2, Pages S105-S111Publisher
MOSBY-ELSEVIER
DOI: 10.1016/mjd.2003.554
Keywords
-
Categories
Ask authors/readers for more resources
Etanercept, a competitive inhibitor of TNF-alpha, is currently FDA approved for psoriatic arthritis and rheumatoid arthritis. The molecular structure of etanercept, its mechanism of action, and results of clinical trials involving patients with psoriasis will be reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available